baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

SHIONOGI + CO. LTD/ JP3347200002 /

1/22/2025 9:52:28 PM	Chg. +0.3000	Volume	Bid7:35:14 AM	Ask7:35:14 AM	Market Capitalization	Dividend Y.	P/E Ratio
13.3000EUR	+2.31%	0 Turnover: 0.0000	13.2000Bid Size: 150	14.5000Ask Size: 150	3.86 bill.EUR	-	-

GlobeNewswire 5/23/2024 Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Preval...

GlobeNewswire 5/9/2024 Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Ni...

GlobeNewswire 5/7/2024 Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal

GlobeNewswire 4/3/2024 Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire 3/6/2024 Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference

GlobeNewswire 2/22/2024 Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference

GlobeNewswire 2/19/2024 InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery

GlobeNewswire 2/7/2024 Alleo Labs Announces Publication on the Use of Artificial Intelligence in Neuroscience Drug Discover...

GlobeNewswire 1/22/2024 Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resourc...

GlobeNewswire 11/10/2023 Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...

GlobeNewswire 11/1/2023 Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for...

GlobeNewswire 10/21/2023 F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TI...

GlobeNewswire 9/20/2023 OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs

GlobeNewswire 12/22/2021 Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Ne...

GlobeNewswire 11/4/2021 Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

TeleTrader 11/1/2021 Shionogi to start COVID vaccine Phase 3 trial

GlobeNewswire 8/23/2021 Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

TeleTrader 7/25/2021 Japanese company tests anti-COVID drug - report

TeleTrader 6/27/2021 Japanese Shionogi to produce 60M doses in 2022

GlobeNewswire 5/13/2021 Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results

GlobeNewswire 4/27/2021 InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration

GlobeNewswire 4/5/2021 Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

GlobeNewswire 2/5/2021 CHNC Saga, Metamorphosis, and Transformation

GlobeNewswire 11/13/2020 AIM ImmunoTech Provides Third Quarter 2020 Business Update

GlobeNewswire 10/30/2020 BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year

SHIONOGI + CO. LTD/ JP3347200002 /

If you wish to receive reply to your feedback, please provide your email address.